RT Journal Article
SR Electronic
T1 Blood group A Secretors are associated with a higher risk of COVID-19 cardiovascular disease complications
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.19.20248172
DO 10.1101/2020.12.19.20248172
A1 TJ Mankelow
A1 BK Singleton
A1 PL Moura
A1 CJ Stevens-Hernandez
A1 NM Cogan
A1 G Gyorffy
A1 S Kupzig
A1 L Nichols
A1 C Asby
A1 J Pooley
A1 G Ruffino
A1 F Hosseini
A1 F Moghaddas
A1 M Attwood
A1 A Noel
A1 A Cooper
A1 D Arnold
A1 F Hamilton
A1 C Hyams
A1 A Finn
A1 AM Toye
A1 DJ Anstee
YR 2020
UL http://medrxiv.org/content/early/2020/12/19/2020.12.19.20248172.abstract
AB The SARS-CoV-2 virus causes COVID-19, an infection capable of causing severe disease and death but which may also be asymptomatic or oligosymptomatic in many individuals. While several risk factors, including age, have been described, the mechanisms of this variation are poorly understood. Several studies have described associations between blood group and COVID-19 severity, while others do not. Expression of ABO glycans on secreted proteins and non-erythroid cells is controlled by a fucosyltransferase (FUT2). Inactivating mutations result in a non-secretor phenotype which is known to protect against some viral infections. We investigated whether ABO or secretor status was associated with COVID-19 severity. Data combined from healthcare records and laboratory tests (n=275) of SARS-CoV-2 PCR positive patients hospitalised with COVID-19, confirmed higher than expected numbers of blood group A individuals compared to O (RR=1.24, CI 95% [1.05,1.47], P=0.0111). There was also a significant association between group A and COVID-19-related cardiovascular complications (RR=2.56, CI 95% [1.43,4.55], P=0.0011) which is independent of gender. Molecular analysis of phenotype revealed that group A patients who are non-secretors are significantly less likely to be hospitalised than secretors. In a larger cohort of 1000 convalescent plasma donors, among whom the majority displayed COVID-19 symptoms and only a small minority required hospitalisation, group A non-secretors were slightly over-represented. Our findings indicate that group A non-secretors are not resistant to infection by SARS-CoV-2, but they are likely to experience a less severe form of its associated disease.Key PointsBlood group type A is associated with an increased risk of cardiovascular complications in COVID-19 patients.FUT2 “non-secretor” status reduces the risk of severe COVID-19 outcomes in patients with blood group A.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Red Cell Products (IS-BTU-1214-10032) and the Department of Health (England) (National Health Service Blood and Transplant research and development grant - WP15-04). C.H is funded by a National Institute for Health Research (NIHR) Academic Clinical Fellowship in Respiratory Medicine. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, or the Department of Health and Social Care. The DISCOVER study was funded by grants from the Southmead Hospital Charity, and support from the Elizabeth Blackwell Institute, University of Bristol.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:A retrospective cohort analysis of COVID-19 infected individuals was undertaken as part of an audit on adult patients hospitalised at North Bristol NHS Trust with COVID-19 infection, was approved by the North Bristol NHS Trust Audit and Research Ethics Committee. DISCOVER samples were collected under HRA ethical approval, reviewed and approved by South Yorkshire Research Ethics Committee REC No.20/YH/0121, Access to, and research on healthy donor and COVID-19 patient samples was undertaken on HRA ethical approval, reviewed and approved by Leeds West Research Ethics Committee (REC No. 20/YH/0168).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData not available due ethical/legal restrictions Due to the nature of this research, participants of this study did not agree for their data to be shared publicly, so supporting data is not available. All available data is located in the manuscript and supplemental data